Revance Therapeutics Inc

NASDAQ:RVNC  
21.55
-0.53 (-2.40%)
7:47:02 PM EDT: $20.82 -0.73 (-3.39%)
Earnings Announcements

Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update

Published: 11/08/2022 21:40 GMT
Revance Therapeutics Inc (RVNC) - Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update.
Submitted Sbla for Daxxify for the Treatment of Cervical Dystonia, With Anticipated PDUFA Date in 2023.
Qtrly Loss per Share $1.17.
Q3 Earnings per Share View $-0.89 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $37.22 Million
Adjusted EPS is expected to be -$0.88

Next Quarter Revenue Guidance is expected to be $40.71 Million
Next Quarter EPS Guidance is expected to be -$0.70

More details on our Analysts Page.